Study population characteristics by antidepressant (ATD) drug group
| ATD drug group | |||||
|---|---|---|---|---|---|
| TCA* | SSRI† | Other‡ | MAOI§ | Any ATD | |
| *Tricyclic antidepressants. | |||||
| †Selective serotonin reuptake inhibitors. | |||||
| ‡Other antidepressants (flupentixol, mirtazapine, nefazodone, reboxetine, tryptophan, venlafaxine). | |||||
| §Monoamine oxidase inhibitors. | |||||
| ¶Subjects were counted more than once if prescribed ATDs from more than one drug group. | |||||
| Prescriptions (%) | 51868 (55.7) | 38429 (41.3) | 2708 (2.9) | 86 (0.1) | 93091 (100.0) |
| Most commonly prescribed drug | Imipramine | Fluoxetine | Venlafaxine | Moclobemide | – |
| Prescriptions (%) | 20938 (22.5) | 18145 (19.5) | 1372 (1.5) | 65 (0.1) | |
| Subjects (%) | 15930 (63.8) | 10480 (42.0) | 1056 (4.2) | 37 (0.1) | 24976 (100.0) |
| Mean age at study entry (SD), y | 12.6 (4.64) | 16.4 (2.04) | 16.5 (1.98) | 15.5 (4.20) | 14.0 (4.35) |
| Boys/girls | 7108/8822 | 2591/7889 | 274/782 | 18/19 | 9422/15554 |
| First time new users (%) | 13382 (60.3) | 8254 (37.2) | 562 (2.5) | 16 (0.1) | 22195 (100.0) |
| Mean age at study entry (SD), y | 12.3 (4.68) | 16.5 (2.03) | 16.6 (2.09) | 15.6 (4.60) | 13.9 (4.37) |
| Age groups: | |||||
| 0–10 years | 5130 | 150 | 9 | 3 | 5292 |
| 11–14 years | 2566 | 714 | 38 | 0 | 3318 |
| 15–18 years | 5686 | 7390 | 515 | 13 | 13604 |